单克隆抗体预防婴幼儿呼吸道合胞病毒感染的研究进展  

Research progress on monoclonal antibody for prevention of respiratory syncytial virus infection in infants

作　　者：李明燕[1] 胡昱[2] 沈建勇[3] 季钗[1] Li Mingyan;Hu Yu;Shen Jianyong;Ji Chai(Department of Children HealthCare,the Children's Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310005,China;Department of Expanded Immunization Program,Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310057,China;Ofice,Huzhou Disease Prevention and Control Center,Huzhou 313099,China)

机构地区：[1]浙江大学医学院附属儿童医院儿童保健科,国家儿童健康与疾病临床医学研究中心,杭州310005 [2]浙江省疾病预防控制中心免疫规划所,杭州310057 [3]湖州市疾病预防控制中心办公室,湖州313099

出　　处：《国际流行病学传染病学杂志》2024年第5期353-358,共6页International Journal of Epidemiology and Infectious Disease

摘　　要：呼吸道合胞病毒(respiratory syncytial virus, RSV)是婴幼儿发生严重呼吸道疾病的主要病因之一。目前RSV感染尚无有效治疗手段, 但可通过疫苗接种或注射被动免疫生物制品进行预防。婴幼儿早期使用单克隆抗体能有效预防RSV感染, 降低重症和死亡率, 本文就RSV单克隆抗体的最新研究进展进行综述。Respiratory syncytial virus(RSV)is one of the major causes of severe respiratory diseases in infants.At present,no effective treatment is available against RSV infection.However,vaccine or passive immune biologics against RSV can offer effective protection.Early use of monoclonal antibody in infants can prevent RSV infection and reduce the incidence of severe disease and death.This article reviews the latest research progress on monoclonal antibodies targeting RSV.

关 键 词：呼吸道合胞病毒 婴幼儿 单克隆抗体 

分 类 号：R725.6[医药卫生—儿科]